# Iovance Biotherapeutics, Inc.: financial statements, quarterly

IOVA · Nasdaq · CIK 1425205 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/iova.md) · [Financials](/companies/iova/financials.md) · [Filings](/companies/iova/filings.md) · [Insiders](/companies/iova/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/iova/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.5](/filings/0001558370-24-014905.md) | [0.5 d](/filings/0001104659-26-018899.md) | [0.7](/filings/0001558370-25-007009.md) | [31.1](/filings/0001558370-25-010807.md) | [58.6](/filings/0001104659-25-107470.md) | [73.7 d](/filings/0001104659-26-018899.md) | [49.3](/filings/0001104659-26-056778.md) | [60.0](/filings/0001104659-26-091716.md) | [67.5](/filings/0001104659-25-107470.md) | [86.8 d](/filings/0001104659-26-018899.md) | [71.4](/filings/0001104659-26-056778.md) | [99.3](/filings/0001104659-26-091716.md) |
| Cost of revenue | $m | [4.3](/filings/0001558370-24-014905.md) | [(5.4) d](/filings/0001104659-26-018899.md) | [7.3](/filings/0001558370-25-007009.md) | [31.4](/filings/0001558370-25-010807.md) | [31.5](/filings/0001104659-25-107470.md) | [37.8 d](/filings/0001104659-26-018899.md) | [42.7](/filings/0001104659-26-056778.md) | [48.9](/filings/0001104659-26-091716.md) | [38.5](/filings/0001104659-25-107470.md) | [43.1 d](/filings/0001104659-26-018899.md) | [42.5](/filings/0001104659-26-056778.md) | [43.6](/filings/0001104659-26-091716.md) |
| Research and development | $m | [87.5](/filings/0001558370-24-014905.md) | [76.6 d](/filings/0001104659-26-018899.md) | [79.8](/filings/0001558370-25-007009.md) | [62.1](/filings/0001558370-25-010807.md) | [67.0](/filings/0001104659-25-107470.md) | [71.0 d](/filings/0001104659-26-018899.md) | [76.0](/filings/0001104659-26-056778.md) | [77.9](/filings/0001104659-26-091716.md) | [75.2](/filings/0001104659-25-107470.md) | [71.2 d](/filings/0001104659-26-018899.md) | [62.5](/filings/0001104659-26-056778.md) | [58.9](/filings/0001104659-26-091716.md) |
| Operating income | $m | [(118)](/filings/0001558370-24-014905.md) | [(121) d](/filings/0001104659-26-018899.md) | [(118)](/filings/0001558370-25-007009.md) | [(102)](/filings/0001558370-25-010807.md) | [(89.1)](/filings/0001104659-25-107470.md) | [(86.6) d](/filings/0001104659-26-018899.md) | [(121)](/filings/0001104659-26-056778.md) | [(114)](/filings/0001104659-26-091716.md) | [(94.9)](/filings/0001104659-25-107470.md) | [(73.5) d](/filings/0001104659-26-018899.md) | [(81.0)](/filings/0001104659-26-056778.md) | [(51.9)](/filings/0001104659-26-091716.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(1.2)](/filings/0001558370-24-014905.md) | [(1.8) d](/filings/0001104659-26-018899.md) | [(1.4)](/filings/0001558370-25-007009.md) | [(1.5)](/filings/0001558370-25-010807.md) | [(1.5)](/filings/0001104659-25-107470.md) | [1.6 d](/filings/0001104659-26-018899.md) | [(1.8)](/filings/0001104659-26-056778.md) | [2.0](/filings/0001104659-26-091716.md) | [(2.4)](/filings/0001104659-25-107470.md) | [0.2 d](/filings/0001104659-26-018899.md) | [(0.7)](/filings/0001104659-26-056778.md) | [(1.4)](/filings/0001104659-26-091716.md) |
| Net income | $m | [(114)](/filings/0001558370-24-014905.md) | [(116) d](/filings/0001104659-26-018899.md) | [(113)](/filings/0001558370-25-007009.md) | [(97.1)](/filings/0001558370-25-010807.md) | [(83.5)](/filings/0001104659-25-107470.md) | [(78.6) d](/filings/0001104659-26-018899.md) | [(116)](/filings/0001104659-26-056778.md) | [(112)](/filings/0001104659-26-091716.md) | [(91.3)](/filings/0001104659-25-107470.md) | [(71.9) d](/filings/0001104659-26-018899.md) | [(79.0)](/filings/0001104659-26-056778.md) | [(47.3)](/filings/0001104659-26-091716.md) |
| Diluted EPS | $ per share | [(0.46)](/filings/0001558370-24-014905.md) | not reported | [(0.42)](/filings/0001558370-25-007009.md) | [(0.34)](/filings/0001558370-25-010807.md) | [(0.28)](/filings/0001558370-24-014905.md) | not reported | [(0.36)](/filings/0001104659-26-056778.md) | [(0.33)](/filings/0001104659-26-091716.md) | not reported | not reported | [(0.19)](/filings/0001104659-26-056778.md) | [(0.11)](/filings/0001104659-26-091716.md) |
| Basic EPS | $ per share | [(0.46)](/filings/0001558370-24-014905.md) | not reported | [(0.42)](/filings/0001558370-25-007009.md) | [(0.34)](/filings/0001558370-25-010807.md) | [(0.28)](/filings/0001104659-25-107470.md) | not reported | [(0.36)](/filings/0001104659-26-056778.md) | [(0.33)](/filings/0001104659-26-091716.md) | [(0.25)](/filings/0001104659-25-107470.md) | not reported | [(0.19)](/filings/0001104659-26-056778.md) | [(0.11)](/filings/0001104659-26-091716.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [268](/filings/0001558370-24-014905.md) | [115](/filings/0001104659-26-018899.md) | [134](/filings/0001558370-25-007009.md) | [229](/filings/0001558370-25-010807.md) | [164](/filings/0001104659-25-107470.md) | [116](/filings/0001104659-26-018899.md) | [172](/filings/0001104659-26-056778.md) | [132](/filings/0001104659-26-091716.md) | [158](/filings/0001104659-25-107470.md) | [163](/filings/0001104659-26-091716.md) | [197](/filings/0001104659-26-056778.md) | [111](/filings/0001104659-26-091716.md) |
| Current assets | $m | [383](/filings/0001558370-23-018029.md) | [308](/filings/0001558370-25-001834.md) | [386](/filings/0001558370-24-007646.md) | [482](/filings/0001558370-24-011641.md) | [499](/filings/0001558370-24-014905.md) | [457](/filings/0001104659-26-018899.md) | [513](/filings/0001558370-25-007009.md) | [423](/filings/0001558370-25-010807.md) | [429](/filings/0001104659-25-107470.md) | [443](/filings/0001104659-26-091716.md) | [467](/filings/0001104659-26-056778.md) | [464](/filings/0001104659-26-091716.md) |
| Total assets | $m | [852](/filings/0001558370-23-018029.md) | [780](/filings/0001558370-25-001834.md) | [870](/filings/0001558370-24-007646.md) | [964](/filings/0001558370-24-011641.md) | [991](/filings/0001558370-24-014905.md) | [910](/filings/0001104659-26-018899.md) | [967](/filings/0001558370-25-007009.md) | [907](/filings/0001558370-25-010807.md) | [905](/filings/0001104659-25-107470.md) | [913](/filings/0001104659-26-091716.md) | [926](/filings/0001104659-26-056778.md) | [916](/filings/0001104659-26-091716.md) |
| Current liabilities | $m | [91.0](/filings/0001558370-23-018029.md) | [110](/filings/0001558370-25-001834.md) | [83.2](/filings/0001558370-24-007646.md) | [93.6](/filings/0001558370-24-011641.md) | [118](/filings/0001558370-24-014905.md) | [122](/filings/0001104659-26-018899.md) | [123](/filings/0001558370-25-007009.md) | [129](/filings/0001558370-25-010807.md) | [126](/filings/0001104659-25-107470.md) | [138](/filings/0001104659-26-091716.md) | [129](/filings/0001104659-26-056778.md) | [107](/filings/0001104659-26-091716.md) |
| Total liabilities | $m | [178](/filings/0001558370-23-018029.md) | [196](/filings/0001558370-25-001834.md) | [190](/filings/0001558370-24-007646.md) | [196](/filings/0001558370-24-011641.md) | [218](/filings/0001558370-24-014905.md) | [200](/filings/0001104659-26-018899.md) | [199](/filings/0001558370-25-007009.md) | [209](/filings/0001558370-25-010807.md) | [203](/filings/0001104659-25-107470.md) | [215](/filings/0001104659-26-091716.md) | [204](/filings/0001104659-26-056778.md) | [179](/filings/0001104659-26-091716.md) |
| Shareholders' equity | $m | [674](/filings/0001558370-24-014905.md) | [585](/filings/0001104659-26-018899.md) | [680](/filings/0001558370-25-010807.md) | [769](/filings/0001104659-25-107470.md) | [773](/filings/0001104659-25-107470.md) | [710](/filings/0001104659-26-091716.md) | [768](/filings/0001104659-26-091716.md) | [698](/filings/0001104659-26-091716.md) | [702](/filings/0001104659-25-107470.md) | [699](/filings/0001104659-26-091716.md) | [722](/filings/0001104659-26-091716.md) | [736](/filings/0001104659-26-091716.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(84.1) d](/filings/0001558370-24-014905.md) | [(84.0) d](/filings/0001104659-26-018899.md) | [(122)](/filings/0001558370-25-007009.md) | [(98.4) d](/filings/0001558370-25-010807.md) | [(59.0) d](/filings/0001104659-25-107470.md) | [(73.3) d](/filings/0001104659-26-018899.md) | [(104)](/filings/0001104659-26-056778.md) | [(67.4) d](/filings/0001104659-26-091716.md) | [(78.7) d](/filings/0001104659-25-107470.md) | [(52.6) d](/filings/0001104659-26-018899.md) | [(72.1)](/filings/0001104659-26-056778.md) | [(60.8) d](/filings/0001104659-26-091716.md) |
| Capital expenditure | $m | [3.6 d](/filings/0001558370-24-014905.md) | [3.5 d](/filings/0001104659-26-018899.md) | [4.2](/filings/0001558370-25-007009.md) | [0.4 d](/filings/0001558370-25-010807.md) | [2.3 d](/filings/0001104659-25-107470.md) | [4.2 d](/filings/0001104659-26-018899.md) | [6.2](/filings/0001104659-26-056778.md) | [7.5 d](/filings/0001104659-26-091716.md) | [10.8 d](/filings/0001104659-25-107470.md) | [9.3 d](/filings/0001104659-26-018899.md) | [6.6](/filings/0001104659-26-056778.md) | [5.4 d](/filings/0001104659-26-091716.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [157](/filings/0001558370-23-013988.md) | [158](/filings/0001558370-23-018029.md) | [214](/filings/0001558370-24-007646.md) | [0.2](/filings/0001558370-24-011641.md) | [0.2](/filings/0001558370-24-014905.md) | [0.3](/filings/0001558370-25-007009.md) | [0.3](/filings/0001558370-25-010807.md) | [0.3](/filings/0001558370-24-014905.md) | [0.3](/filings/0001104659-26-056778.md) | [0.3](/filings/0001104659-26-091716.md) | [0.4](/filings/0001104659-26-056778.md) | [0.5](/filings/0001104659-26-091716.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 452,971,432 at 2026-07-29, from the cover of the [10-Q filed 2026-08-06](/filings/0001104659-26-091716.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.